Related Experiment Videos
Paroxetine: a pharmacological review
1SmithKline Beecham Pharmaceuticals, Welwyn, Hertfordshire, UK.
International Clinical Psychopharmacology
|June 1, 1992
Summary
Paroxetine is a potent and selective serotonin reuptake inhibitor, effective for depression treatment. Its pharmacokinetic profile supports once-daily dosing and demonstrates advantages over older antidepressants.
Area of Science:
- Pharmacology
- Neuroscience
- Clinical Psychiatry
Background:
- Paroxetine is identified as a potent and selective inhibitor of 5-hydroxytryptamine (serotonin) reuptake.
- Its selectivity extends beyond monoamine uptake to neurotransmitter receptor systems.
Purpose of the Study:
- To characterize the pharmacological and pharmacokinetic profile of paroxetine.
- To evaluate its efficacy and tolerability as an antidepressant.
- To compare its advantages against tricyclic antidepressants and other SSRIs.
Main Methods:
- Pharmacokinetic studies to determine dosing and metabolite activity.
- Clinical studies to assess antidepressant efficacy and tolerability.
Main Results:
- Paroxetine demonstrates high potency and selectivity for serotonin reuptake.
- Pharmacokinetic data suggest once-daily administration with steady-state achieved in 7-14 days.
- Paroxetine metabolites do not contribute to clinical effects.
- Clinical studies confirm efficacy and good tolerability.
Conclusions:
- Paroxetine's selectivity and pharmacokinetic profile support its use as an effective antidepressant.
- It offers significant advantages over tricyclic antidepressants and other selective serotonin reuptake inhibitors (SSRIs).